{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T03:41:20Z","timestamp":1777002080776,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Gilead Sciences, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12325-025-03379-1","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T06:35:02Z","timestamp":1761374102000},"page":"6261-6277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Persistence in Adults with HIV and Mental Health or Substance Use Disorders After Restarting Antiretroviral Therapy in the United States"],"prefix":"10.1007","volume":"42","author":[{"given":"Amanda M.","family":"Kong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Lucia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary J.","family":"Christoph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uche","family":"Mordi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisha","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulce","family":"Askin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Yucuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neia Prata","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"3379_CR1","unstructured":"Centers for Disease Control and Prevention. HIV surveillance report: diagnoses, deaths, and prevalence of HIV in the United States and 6 territories and freely associated states. https:\/\/stacks.cdc.gov\/view\/cdc\/156509. Accessed 29 May 2025."},{"issue":"12","key":"3379_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081355","volume":"8","author":"H Samji","year":"2013","unstructured":"Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE. 2013;8(12):e81355.","journal-title":"PLoS ONE"},{"key":"3379_CR3","unstructured":"Centers for Disease Control and Prevention. Ending the HIV epidemic in the US (EHE). https:\/\/www.cdc.gov\/ehe\/index.html. Accessed 29 May 2025."},{"key":"3379_CR4","unstructured":"US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf. Accessed 29 May 2025."},{"issue":"4","key":"3379_CR5","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1086\/596482","volume":"48","author":"JJ Parienti","year":"2009","unstructured":"Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48(4):484\u20138.","journal-title":"Clin Infect Dis"},{"key":"3379_CR6","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.2147\/PPA.S207908","volume":"13","author":"DM Hines","year":"2019","unstructured":"Hines DM, Ding Y, Wade RL, Beaubrun A, Cohen JP. Treatment adherence and persistence among HIV-1 patients newly starting treatment. Patient Prefer Adherence. 2019;13:1927\u201339.","journal-title":"Patient Prefer Adherence"},{"issue":"11","key":"3379_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002183","volume":"13","author":"Z Shubber","year":"2016","unstructured":"Shubber Z, Mills EJ, Nachega JB, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med. 2016;13(11):e1002183.","journal-title":"PLoS Med"},{"issue":"3","key":"3379_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/13548506.2014.945601","volume":"20","author":"KR Claborn","year":"2015","unstructured":"Claborn KR, Meier E, Miller MB, Leffingwell TR. A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy. Psychol Health Med. 2015;20(3):255\u201365.","journal-title":"Psychol Health Med"},{"issue":"1","key":"3379_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/QAI.0000000000000084","volume":"66","author":"AJ Hughes","year":"2014","unstructured":"Hughes AJ, Mattson CL, Scheer S, Beer L, Skarbinski J. Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States. J Acquir Immune Defic Syndr. 2014;66(1):80\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"3379_CR10","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1111\/hiv.13653","volume":"25","author":"JJ Matacotta","year":"2024","unstructured":"Matacotta JJ, Tran D, Yoon S. The prevalence of major depressive disorder in people with HIV: results from the All of Us Research Program. HIV Med. 2024;25(8):998\u20131004.","journal-title":"HIV Med"},{"issue":"9651","key":"3379_CR11","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/S0140-6736(08)61311-2","volume":"372","author":"BM Mathers","year":"2008","unstructured":"Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733\u201345.","journal-title":"Lancet"},{"issue":"4","key":"3379_CR12","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s10461-016-1584-6","volume":"21","author":"B Hartzler","year":"2017","unstructured":"Hartzler B, Dombrowski JC, Crane HM, et al. Prevalence and predictors of substance use disorders among HIV care enrollees in the United States. AIDS Behav. 2017;21(4):1138\u201348.","journal-title":"AIDS Behav"},{"issue":"8","key":"3379_CR13","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1007\/s10461-012-0212-3","volume":"16","author":"SA Springer","year":"2012","unstructured":"Springer SA, Dushaj A, Azar MM. The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV\/AIDS: a systematic review. AIDS Behav. 2012;16(8):2119\u201343.","journal-title":"AIDS Behav"},{"issue":"8","key":"3379_CR14","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/09540120701294245","volume":"19","author":"TW Kim","year":"2007","unstructured":"Kim TW, Palepu A, Cheng DM, Libman H, Saitz R, Samet JH. Factors associated with discontinuation of antiretroviral therapy in HIV-infected patients with alcohol problems. AIDS Care. 2007;19(8):1039\u201347.","journal-title":"AIDS Care"},{"issue":"9","key":"3379_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11908-018-0636-7","volume":"20","author":"ME Socias","year":"2018","unstructured":"Socias ME, Milloy MJ. Substance use and adherence to antiretroviral therapy: what is known and what is unknown. Curr Infect Dis Rep. 2018;20(9):36.","journal-title":"Curr Infect Dis Rep"},{"issue":"2","key":"3379_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/QAD.0000000000003420","volume":"37","author":"R Lang","year":"2023","unstructured":"Lang R, Hogan B, Zhu J, et al. The prevalence of mental health disorders in people with HIV and the effects on the HIV care continuum. AIDS. 2023;37(2):259\u201369.","journal-title":"AIDS"},{"issue":"5","key":"3379_CR17","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.psym.2014.08.004","volume":"56","author":"C O'Cleirigh","year":"2015","unstructured":"O\u2019Cleirigh C, Magidson JF, Skeer MR, Mayer KH, Safren SA. Prevalence of psychiatric and substance abuse symptomatology among HIV-infected gay and bisexual men in HIV primary care. Psychosomatics. 2015;56(5):470\u20138.","journal-title":"Psychosomatics"},{"issue":"4","key":"3379_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1037\/a0032694","volume":"68","author":"JA Pellowski","year":"2013","unstructured":"Pellowski JA, Kalichman SC, Matthews KA, Adler N. A pandemic of the poor: social disadvantage and the U.S. HIV epidemic. Am Psychol. 2013;68(4):197\u2013209.","journal-title":"Am Psychol"},{"issue":"1","key":"3379_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10461-023-04150-9","volume":"28","author":"T O'Grady","year":"2024","unstructured":"O\u2019Grady T, Inman N, Younger A, et al. The characteristics and HIV-related outcomes of people living with co-occurring HIV and mental health conditions in the United States: a systematic review of literature from 2016 to 2021. AIDS Behav. 2024;28(1):201\u201324.","journal-title":"AIDS Behav"},{"issue":"9","key":"3379_CR20","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1093\/cid\/cix570","volume":"65","author":"L Wang","year":"2017","unstructured":"Wang L, Min JE, Zang X, et al. Characterizing human immunodeficiency virus antiretroviral therapy interruption and resulting disease progression using population-level data in British Columbia, 1996\u20132015. Clin Infect Dis. 2017;65(9):1496\u2013503.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"3379_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/hiv.12901","volume":"21","author":"D Van Beckhoven","year":"2020","unstructured":"Van Beckhoven D, Florence E, De Wit S, et al. Incidence rate, predictors and outcomes of interruption of HIV care: nationwide results from the Belgian HIV cohort. HIV Med. 2020;21(9):557\u201366.","journal-title":"HIV Med"},{"key":"3379_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000004171","author":"G Moyle","year":"2025","unstructured":"Moyle G, Gruber J, Dunbar M, et al. Outcomes in people with HIV who resume or switch to bictegravir\/emtricitabine\/tenofovir alafenamide following a treatment interruption. AIDS. 2025. https:\/\/doi.org\/10.1097\/QAD.0000000000004171.","journal-title":"AIDS"},{"issue":"5","key":"3379_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/cid\/ciab541","volume":"74","author":"JZ Li","year":"2022","unstructured":"Li JZ, Aga E, Bosch RJ, et al. Time to viral rebound after interruption of modern antiretroviral therapies. Clin Infect Dis. 2022;74(5):865\u201370.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"3379_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26349","volume":"27","author":"MJ Lee","year":"2024","unstructured":"Lee MJ, Eason M, Castagna A, et al. The impact of analytical treatment interruptions and trial interventions on time to viral re-suppression in people living with HIV restarting ART in cure-related clinical studies: a systematic review and meta-analysis. J Int AIDS Soc. 2024;27(8):e26349.","journal-title":"J Int AIDS Soc"},{"key":"3379_CR25","unstructured":"Owens PL, Weiss AJ, Barrett ML. Hospital burden of opioid-related inpatient stays: metropolitan and rural hospitals, 2016. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020."},{"issue":"8","key":"3379_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1089\/108729103322277420","volume":"17","author":"CA Mellins","year":"2003","unstructured":"Mellins CA, Kang E, Leu CS, Havens JF, Chesney MA. Longitudinal study of mental health and psychosocial predictors of medical treatment adherence in mothers living with HIV disease. AIDS Patient Care STDS. 2003;17(8):407\u201316.","journal-title":"AIDS Patient Care STDS"},{"issue":"2","key":"3379_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/09540120410001641048","volume":"16","author":"K Ingersoll","year":"2004","unstructured":"Ingersoll K. The impact of psychiatric symptoms, drug use, and medication regimen on non-adherence to HIV treatment. AIDS Care. 2004;16(2):199\u2013211.","journal-title":"AIDS Care"},{"issue":"2","key":"3379_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2217\/hiv.10.4","volume":"4","author":"NB Palmer","year":"2010","unstructured":"Palmer NB, Basinski JR, Uldall KK. Psychiatric illness, access and adherence to HAART: a brief review of recent findings and implications for care. HIV Ther. 2010;4(2):215\u201330.","journal-title":"HIV Ther"},{"issue":"6","key":"3379_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233842","volume":"15","author":"TL Rowell-Cunsolo","year":"2020","unstructured":"Rowell-Cunsolo TL, Hu G. Barriers to optimal antiretroviral therapy adherence among HIV-infected formerly incarcerated individuals in New York City. PLoS ONE. 2020;15(6):e0233842.","journal-title":"PLoS ONE"},{"issue":"2","key":"3379_CR30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/09540120802001705","volume":"21","author":"CA Mellins","year":"2009","unstructured":"Mellins CA, Havens JF, McDonnell C, et al. Adherence to antiretroviral medications and medical care in HIV-infected adults diagnosed with mental and substance abuse disorders. AIDS Care. 2009;21(2):168\u201377.","journal-title":"AIDS Care"},{"issue":"4","key":"3379_CR31","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/1354850021000015267","volume":"7","author":"CA Mellins","year":"2002","unstructured":"Mellins CA, Havens JF, McCaskill EO, Leu CS, Brudney K, Chesney MA. Mental health, substance use and disclosure are significantly associated with the medical treatment adherence of HIV-infected mothers. Psychol Health Med. 2002;7(4):451\u201360.","journal-title":"Psychol Health Med"},{"issue":"4","key":"3379_CR32","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/jac\/dkab481","volume":"77","author":"J Ambrosioni","year":"2022","unstructured":"Ambrosioni J, Rojas Lievano J, Berrocal L, et al. Real-life experience with bictegravir\/emtricitabine\/tenofovir alafenamide in a large reference clinical centre. J Antimicrob Chemother. 2022;77(4):1133\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"3379_CR33","unstructured":"Elion R, Dunbar M, Rivet Amico K, et al. Exploring antiretroviral therapy (ART) switch decisions in clinical setting: Trio Health mixed methods study. Presented at IDWeek 2023; October 11\u201315, 2023; Boston, MA, USA. 2023."},{"key":"3379_CR34","unstructured":"HIV.gov. Mental health. https:\/\/www.hiv.gov\/hiv-basics\/staying-in-hiv-care\/other-related-health-issues\/mental-health. Accessed 29 May 2025."},{"issue":"1","key":"3379_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12981-019-0257-8","volume":"17","author":"P Chan","year":"2020","unstructured":"Chan P, Goh O, Kroon E, et al. Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort. AIDS Res Ther. 2020;17(1):1.","journal-title":"AIDS Res Ther"},{"key":"3379_CR36","unstructured":"Sax PE, Eron JJ, Radtchenko J, et al. What influences switching to DTG\/3TC vs. B\/F\/TAF in clinical practice? Presented at the 30th Conference on Retroviruses and Opportunistic Infections; February 19\u201322, 2023; Seattle, WA, USA. 2023."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03379-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03379-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03379-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:04:23Z","timestamp":1763132663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03379-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3379"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03379-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amanda M Kong, Jacqueline Lucia, Daisha Joseph, Gulce Askin, and Daniela Yucuma are employees of and may own stock options in Aetion, Inc., which received funding from Gilead Sciences, Inc., to conduct this analysis. Mary J Christoph, Uche Mordi, Neia Prata Menezes, Peter McMahon, and Travis Lim are employees of and may own stock or stock options in Gilead Sciences, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted using retrospectively collected data and received a formal institutional review board exemption. The data contained no personal identification fields. No informed consent was obtained to participate in this secondary analysis of existing data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}